Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsPreferred Shares RepurchasedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Cash from Financing Activities (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Cash from Financing Activities for 17 consecutive years, with $543779.0 as the latest value for Q1 2026.

  • Quarterly Cash from Financing Activities rose 113.78% to $543779.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.6 million through Jan 2026, up 118.51% year-over-year, with the annual reading at -$25.0 million for FY2025, 133.74% down from the prior year.
  • Cash from Financing Activities for Q1 2026 was $543779.0 at PharmaCyte Biotech, down from $6.2 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $6.3 million in Q3 2023, with the low at -$10.7 million in Q4 2024.
  • Average Cash from Financing Activities over 5 years is -$2.8 million, with a median of -$3.4 million recorded in 2022.
  • Peak annual rise in Cash from Financing Activities hit 400.44% in 2023, while the deepest fall reached 8376.76% in 2023.
  • Over 5 years, Cash from Financing Activities stood at -$3.4 million in 2022, then skyrocketed by 122.12% to $748687.0 in 2023, then tumbled by 1534.56% to -$10.7 million in 2024, then surged by 157.8% to $6.2 million in 2025, then tumbled by 91.24% to $543779.0 in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $543779.0, $6.2 million, and -$171543.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.